The Chinese authorities have granted a marketing authorisation for Pierre Fabre Laboratories’ Braftovi, in combination with cetuximab, for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer, after prior systemic therapy. 

The approval is based on the Phase III BEACON CRC trial, which demonstrated a significant improvement in overall survival of patients treated with Braftovi in combination with cetuximab, as well as on the bridging study NAUTICAL CRC which demonstrated similar results in Chinese patients.  

According to the BEACON CRC trial, the data showed that Braftovi in combination with cetuximab significantly improved overall survival in patients with BRAFV600E-mutant mCRC and the risk of death was reduced by 40% in BEACON CRC and 45% in NAUTICAL CRC. 

NAUTICAL CRC achieved its primary objective, demonstrating an estimated 63% reduction in the risk of disease progression or death among Chinese subjects receiving the Braftovi combination compared to the control group. 

“The marketing authorisation for Braftovi by the Chinese health authorities is a key milestone. Greater China is a priority strategic country for Pierre Fabre Laboratories. We are proud to bring this therapeutic option to Chinese patients fighting BRAFV600E-mutant mCRC, and our teams are poised to make the launch a success in partnership with Chinese authorities and health care professionals,” said Marie-Andrée Gamache, CEO of Pierre Fabre Medical Care. 

BRAF mutations are estimated to occur in approximately 3-5% of Chinese patients with mCRC, with V600E being the most common mutation. 

BRAFTOVI is an oral small molecule kinase inhibitor that targets BRAFV600E. Inappropriate activation of proteins in the MAPK signalling pathway (RAS-RAF-MEK-ERK) has been shown to occur in certain cancers, including CRC. 

Pierre Fabre Laboratories has exclusive rights to commercialise Braftovi in Europe and Asia (excluding Japan and South Korea), with other regions controlled by Pfizer, Ono and Medison. 

Diana Turner, Senior Digital Content Editor, DDW